DLBCL arising from indolent lymphomas: How are they different?

Transformation to diffuse large B-cell lymphoma (DLBCL) is a recognized, but unpredictable, clinical inflection point in the natural history of indolent lymphomas. Large retrospective studies highlight a wide variability in the incidence of transformation across the indolent lymphomas and the adverse outcomes associated with transformed lymphomas. Opportunities to dissect the biology of transformed indolent lymphomas have arisen with evolving technologies and unique tissue collections enabling a growing appreciation, particularly, of their genetic basis, how they relate to the preceding indolent lymphomas and the comparative biology with de novo DLBCL. This review summarizes our current understanding of both the clinical and biological aspects of transformed lymphomas and the outstanding questions that remain.

[1]  S. Leppä,et al.  Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study , 2023, Blood cancer journal.

[2]  Ryan D. Morin,et al.  Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns , 2023, Blood.

[3]  E. Giné,et al.  Unraveling the genetics of transformed splenic marginal zone lymphoma , 2023, Blood advances.

[4]  B. Nadel,et al.  Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors. , 2023, Cancer discovery.

[5]  V. Meignin,et al.  Exploring the genetic landscape of HCV-related B-cell lymphomas using whole exome sequencing , 2023, Leukemia.

[6]  Catherine J. Wu,et al.  Richter syndrome: Novel insights into the biology of transformation. , 2023, Blood.

[7]  A. Rosenwald,et al.  Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis , 2023, Nature Communications.

[8]  J. Byrd,et al.  Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation , 2023, Nature Communications.

[9]  Shuqiang Li,et al.  Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome , 2023, Nature Medicine.

[10]  Shuqiang Li,et al.  In vivo modeling of CLL transformation to Richter's syndrome reveals convergent evolutionary paths and therapeutic vulnerabilities. , 2022, Blood cancer discovery.

[11]  S. Beà,et al.  Generation of Richter Transformation Models throughout Chronic Lymphocytic Leukemia Patient-Derived Xenografts: A Clonal Evolution Model , 2022, Blood.

[12]  Ryan D. Morin,et al.  Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk , 2022, Nature Communications.

[13]  W. Hiddemann,et al.  Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study. , 2022, Clinical lymphoma, myeloma & leukemia.

[14]  D. Torrents,et al.  Detection of early seeding of Richter transformation in chronic lymphocytic leukemia , 2022, Nature Medicine.

[15]  C. Flowers,et al.  Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression , 2022, Blood cancer discovery.

[16]  U. Jaeger,et al.  Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab , 2022, Blood.

[17]  M. Dimopoulos,et al.  High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia , 2022, Blood advances.

[18]  E. Zucca,et al.  Marginal-Zone Lymphomas. , 2022, The New England journal of medicine.

[19]  A. Schuh,et al.  Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. , 2021, The Lancet. Haematology.

[20]  Ryan D. Morin,et al.  Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes? , 2021, British journal of haematology.

[21]  Catherine J. Wu,et al.  Understanding CLL biology through mouse models of human genetics. , 2021, Blood.

[22]  J. Byrd,et al.  Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Pettitt,et al.  Is it time for PET-guided therapy in follicular lymphoma. , 2021, Blood.

[24]  Ash A. Alizadeh,et al.  Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA , 2021, Nature Biotechnology.

[25]  R. Foà,et al.  The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation , 2021, Haematologica.

[26]  S. Barrans,et al.  Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network , 2021, Blood advances.

[27]  Brijesh Singh Yadav,et al.  B Cell Receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter Transformation. , 2021, Blood.

[28]  Hanlee P. Ji,et al.  Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma. , 2021, Blood.

[29]  L. Sehn,et al.  Diffuse Large B-Cell Lymphoma. , 2021, The New England journal of medicine.

[30]  Michael R. Green,et al.  BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma , 2021, Leukemia.

[31]  N. Popitsch,et al.  Genomic and transcriptomic correlates of Richter's transformation in Chronic Lymphocytic Leukemia. , 2020, Blood.

[32]  R. Neve,et al.  KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas , 2020, bioRxiv.

[33]  Ryan D. Morin,et al.  A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. , 2020, Cancer cell.

[34]  S. Barrans,et al.  Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. , 2020, Blood.

[35]  M. Hallek,et al.  Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials , 2020, Leukemia.

[36]  S. Treon,et al.  Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Calaminici,et al.  IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. , 2020, Blood.

[38]  T. Habermann,et al.  Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia , 2019, American journal of hematology.

[39]  Craig R Soderquist,et al.  Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B‐cell lymphoma , 2019, American journal of hematology.

[40]  D. Scott,et al.  Early progression after BR is associated with high risk of transformation in advanced stage follicular lymphoma. , 2019, Blood.

[41]  Lisa L. Smith,et al.  Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma , 2019, Clinical Cancer Research.

[42]  Hanlee P. Ji,et al.  Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints. , 2019, Blood.

[43]  L. Staudt,et al.  Taming the Heterogeneity of Aggressive Lymphomas for Precision Therapy , 2019, Annual Review of Cancer Biology.

[44]  Michael R. Green,et al.  Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma , 2019, bioRxiv.

[45]  J. Cerhan,et al.  Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  N. Munshi,et al.  Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. , 2018, Blood advances.

[47]  I. Lossos,et al.  Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Angela N. Brooks,et al.  Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. , 2018, JCI insight.

[49]  B. Nadel,et al.  Human germinal center transcriptional programs are de-synchronized in B cell lymphoma , 2018, Nature Immunology.

[50]  E. Kimby,et al.  Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. , 2018, The Lancet. Haematology.

[51]  W. Tam,et al.  Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. , 2018, Cancer research.

[52]  M. Horger,et al.  Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales , 2018, Annals of Hematology.

[53]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[54]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[55]  M. Calaminici,et al.  Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma , 2018, Leukemia.

[56]  Julio Delgado,et al.  Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group , 2017, British journal of haematology.

[57]  G. R. Ordóñez,et al.  From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation , 2017, Blood Cancer Journal.

[58]  Yupeng Cun,et al.  Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia , 2017, Nature Communications.

[59]  R. Gascoyne,et al.  Can histologic transformation of follicular lymphoma be predicted and prevented? , 2017, Blood.

[60]  Jeffrey A Jones,et al.  BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  A. Schuh,et al.  Diagnostic dilemmas of high‐grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP‐OR clinical trial specialist haemato‐pathology central review , 2016, Histopathology.

[62]  Ryan D. Morin,et al.  Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study , 2016, PLoS medicine.

[63]  Ash A. Alizadeh,et al.  Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA , 2016, Science Translational Medicine.

[64]  S. Treon,et al.  Histological transformation to diffuse large B‐cell lymphoma in patients with Waldenström macroglobulinemia , 2016, American journal of hematology.

[65]  G. Salles,et al.  Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  A Rosenwald,et al.  Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma , 2016, Leukemia.

[67]  F. Cavalli,et al.  Histologic transformation in marginal zone lymphomas†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  R. Gascoyne,et al.  Cell of origin of transformed follicular lymphoma. , 2015, Blood.

[69]  J. Friedberg,et al.  Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). , 2015, Blood.

[70]  Ash A. Alizadeh,et al.  Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation , 2015, Proceedings of the National Academy of Sciences.

[71]  R. Foà,et al.  Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease , 2015, Leukemia.

[72]  O. Elemento,et al.  Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients. , 2015, Human pathology.

[73]  B. Nadel,et al.  t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  T. Shanafelt,et al.  How we treat Richter syndrome. , 2014, Blood.

[75]  L. Staudt,et al.  Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. , 2014, Blood.

[76]  Raul Rabadan,et al.  Genetics of follicular lymphoma transformation. , 2014, Cell reports.

[77]  M. Calaminici,et al.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.

[78]  Raul Rabadan,et al.  Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome , 2013, The Journal of experimental medicine.

[79]  W. Chan,et al.  Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. , 2013, Blood.

[80]  J. Cerhan,et al.  Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  T. Habermann,et al.  Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients , 2013, British journal of haematology.

[82]  E. Giné,et al.  Plasmablastic Transformation of Low-grade B-cell Lymphomas: Report on 6 Cases , 2013, The American journal of surgical pathology.

[83]  E. Jaffe,et al.  Clonally related Histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: A study of 7 cases , 2011, Modern Pathology.

[84]  S. Pileri,et al.  The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. , 2011, Blood.

[85]  Stine H. Kresse,et al.  Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. , 2010, Blood.

[86]  Francesco Bertoni,et al.  Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome , 2009, Clinical Cancer Research.

[87]  J. Gribben,et al.  Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. , 2009, Blood.

[88]  Randy D Gascoyne,et al.  Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  R. Warnke,et al.  Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. , 2008, Blood.

[90]  A. Rosenwald,et al.  IgVH Mutational Status and Clonality Analysis of Richter's Transformation: Diffuse Large B-cell Lymphoma and Hodgkin Lymphoma in Association With B-cell Chronic Lymphocytic Leukemia (B-CLL) Represent 2 Different Pathways of Disease Evolution , 2007, The American journal of surgical pathology.

[91]  M. Calaminici,et al.  Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  K. Do,et al.  Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  B. Nadel,et al.  Follicular lymphoma dynamics. , 2021, Advances in immunology.

[94]  D. Neuberg,et al.  Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. , 2012, Cancer discovery.